Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Nasdaq outshines Wall St peers on tech boost, earnings glee
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Hasbro (HAS) brand strength sees earnings top expectations
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Merck (MRK) Nears Deal to Buy Acceleron Pharma (XLRN) - DJ
September 27, 2021 5:34 PM EDT(Updated - September 27, 2021 5:37 PM EDT)
Merck (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma (NASDAQ: XLRN), according to Dow Jones, citing people familiar with the matter.
The deal for could be announced this week.
Bloomberg earlier reported the company was it talks with an unnamed buyer.
... MoreAcceleron Pharma (XLRN) $180/Sh Rumored Takeover Price 'Too Low' - Cowen
September 27, 2021 1:22 PM EDTCowen analyst Yaron Werber weighed in on Acceleron Pharma (NASDAQ: XLRN) following reports the company is in advanced talks to be acquired for $180/share. Werber sees that price as "too low" to get a deal done.
"If true, we believe... More
Pre-Open Stock Movers 09/27: (RCAT) (NKAD) (XLRN) Higher; (BHVN) (RIDE) (H) Lower (more...)
September 27, 2021 9:17 AM EDTPre-Open Stock Movers:
Red Cat Holdings, Inc. (Nasdaq: RCAT) 50% HIGHER; announces its subsidiary, Skypersonic, Inc., a leader in Confined Space drone technology, has been awarded a five-year contract with NASA to provide drone and rover software, hardware and support for its Simulated Mars mission.
Analyst Sees Rumored $11B Price For Acceleron (XLRN) as 'Too Low,' Says $13B to $14B a Fair Value, Bristol-Myers Squibb (BMY) Seen as a 'Natural Buyer'
September 27, 2021 7:35 AM EDTRaymond James analyst Danielle Brill has weighed in on Fridays report in Bloomberg that noted Acceleron (NASDAQ: XLRN) is in advanced talks over a potential $11 billion sale with an unidentified buyer.
The drugmaker is reportedly in advanced talks to be acquired by a... More
Acceleron Pharma (XLRN) Said in Advanced Talks for $11 Billion Sale - Bloomberg
September 27, 2021 6:31 AM EDTAcceleron Pharma (NASDAQ: XLRN) is in advanced discussions to be acquired by a large pharmaceutical company for about $180 per share in cash, according to a report from Bloomberg after the market closed on Friday. The identity of the potential buyer couldn't be... More
Acceleron Pharma (XLRN) PT Raised to $179 at RBC Capital
September 27, 2021 6:07 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Acceleron Pharma (NASDAQ: XLRN) to $179.00 (from $113.00) while maintaining a Sector Perform rating.... More
